AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles.
Study NCT03811509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonate
Description: antiresorptives
Study NCT01964235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 will be administered orally and continuously on a twice a day dosing schedule.
Study NCT01964235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally and continuously on a twice a day dosing schedule.
Study NCT01133171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Alone
Description: Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
Study NCT01133171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard Plus Nurse
Description: Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT03179904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT01770600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill administered daily for 5 days
Study NCT01770600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riperidone
Description: 1 mg risperidone administered orally for 5 days
Study NCT01128829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 60 ml of water were drank 10 min before doing a OGTT
Study NCT01128829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
Study NCT03308396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Days 1-5 Dose 0: 60 mg/m\^2 Dose -1: 45 mg/m\^2
Study NCT03308396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Day 8 Durvalumab (1500 mg IV)
Study NCT03987087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
Study NCT03987087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
Study NCT03875950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician training intervention
Description: This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
Study NCT04545255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave treatment
Description: ED 1000 shockwave generator
Study NCT04545255 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shockwave treatment
Description: ED 1000 shockwave generator
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03179904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT05461638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides
Description: MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
Study NCT05461638 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides
Description: MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
Study NCT02817412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go/No-Training
Study NCT02817412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop-Signal Training
Study NCT02817412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dot-Probe Paradigm
Study NCT02817412 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Generic Response Training
Study NCT02745561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatins
Description: Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
Study NCT03179904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03179904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03179904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03179904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02501187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levator advancement
Description: A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
Study NCT02501187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Müller's muscle-conjunctival resection procedure
Description: A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
Study NCT02501187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White line advancement
Description: A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
Study NCT03135418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient.
Study NCT03135418 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
Study NCT02745561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
Study NCT02745561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
Study NCT02052557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Study NCT02052557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposome suspension
Description: 30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Study NCT02532270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
Study NCT01375764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01375764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Administered orally once a day
Study NCT01375764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study NCT01375764 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection
Study NCT02170272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Lymphedema Care Program
Description: Undergo HBLCP
Study NCT03944239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retinal pigment epitheliums transplantation
Description: Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
Study NCT01557166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Study NCT01557166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
Study NCT02990260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces cerevisiae
Description: Live Saccharomyces cerevisiae
Study NCT02990260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lynside Wall Basic
Description: yeast cell walls
Study NCT02990260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maize starch and magnesium stearate
Study NCT03551743 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Edoxaban
Study NCT03551743 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Edoxaban
Study NCT03551743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01465659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO
Study NCT01465659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT02547480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE with irinotecan loaded LifePearl
Description: Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
Study NCT02570269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AuraGain
Description: Fiberoptic Intubation
Study NCT02570269 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Slotted Guedeltubus
Description: Fiberoptic Intubation
Study NCT04023955 — intervention group
Intervention type: BEHAVIORAL
Intervention: Twitter
Description: Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
Study NCT04468217 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples
Description: Each patient will undergo a sample collection where two nasopharyngeal samples will be obtained, one of them with lysis buffer as the transport medium and the other with the AAA-Safe solution as the transport medium. Oropharyngeal, buccal, nasal, and salivary samples will also be obtained using AAA-Safe as the transport medium
Study NCT03793387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF-guided endobronchial marking
Description: Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
Study NCT03793387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENB-guided endobronchial marking
Description: Bronchoscopic dye marking with ENB system
Study NCT03073473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NantHealth GPS Cancer Test
Description: Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
Study NCT03418012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical pessary
Description: Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
Study NCT03418012 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control-Group
Description: Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
Study NCT03190408 — intervention group
Intervention type: OTHER
Intervention: Fluids
Description: Fluids Administered in Shock
Study NCT00817011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Study NCT00817011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-SSRI treated group
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Study NCT03140904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard weekly visits
Description: Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
Study NCT03140904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Monthly visits
Description: Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
Study NCT01465308 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey mouthwash
Description: The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
Study NCT01465308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
Study NCT02916654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrosomial iron
Description: administration of sucrosomial iron
Study NCT02916654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphate iron
Description: administration of sulphate iron
Study NCT01791855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
Study NCT01791855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
Study NCT01791855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
Study NCT01791855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
Study NCT00401063 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: Acupuncture treatment twice a day for eight weeks
Study NCT05004545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
Study NCT05004545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
Study NCT03174145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive behaviour
Description: Information about T4P1010 treatment
Study NCT03174145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T4P1010 administration
Description: Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
Study NCT03174145 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic
Description: Blood sample of 10 millilitres maximum
Study NCT03174145 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Pharmacogenetic
Description: Blood sample of 10 millilitres maximum
Study NCT03174145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires and diary completion
Description: Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
Study NCT03174145 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires and diary completion
Description: Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
Study NCT03116945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Gallium Citrate
Description: Procedure: PET/CT Imaging
Study NCT04208854 — intervention group
Intervention type: DRUG
Intervention: Vinorelbine
Description: Vinorelbine 40 mg (2 cps of 20 mg) three times a week (Monday. Wednesday, Friday), for the first 2 weeks.~Starting from the third week, in the absence of any severe toxicity (≥ 3) and in the opinion of the clinician, the dosage can be increased to 50 mg (1 cps from 30 + 1 cps from 20 mg), three times a week ( Monday, Wednesday, Friday) continuously.~The dosage of 40 or 50 mg is continued until progression, patient refusal or unacceptable toxicity (in the clinician's opinion).
Study NCT03632980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablatherm Foc/Dyn or Focal One HIFU treatment
Description: Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application.
Study NCT03611426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhThrombin ( Topical )
Description: Active Substance
Study NCT03611426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline solution
Study NCT01407094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 50-200mg/day
Study NCT01407094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-4 pills per day
Study NCT01407094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BupropionXL
Description: 150-450 mg/day